Castle Biosciences Wins Genomics Innovation Award for AdvanceAD-Tx Test in Atopic Dermatitis.

Castle Biosciences, Inc. (CSTL) has gained a significant accolade, winning the 'Genomics Innovation Award' at the 10th annual MedTech Breakthrough Awards for its AdvanceAD-Tx test. This award reflects the company’s dedication to advancing healthcare solutions that focus on patient outcomes.

AdvanceAD-Tx Test Revolutionizes Atopic Dermatitis Treatment

The AdvanceAD-Tx test serves as a clinically validated gene expression profile (GEP) tool that aids in making systemic treatment decisions for patients diagnosed with moderate-to-severe atopic dermatitis. Utilizing a non-invasive skin scraping method, the test analyzes 487 genes linked to the condition across various skin and inflammatory pathways. Through the generation of both a Janus kinase (JAK) Inhibitor Responder Profile and a T-helper 2 (Th2) Molecular Profile, AdvanceAD-Tx empowers clinicians to make more accurate therapy selections tailored to individual patient needs.

Derek Maetzold, CEO of Castle Biosciences, notes that patients aligned with their AdvanceAD-Tx results are 5.5 times more likely to achieve clearer skin and experience quicker symptom relief compared to traditional treatment options. This breakthrough is not merely academic; it underscores a vital need for innovative diagnostics in chronic skin conditions, which are often challenging to manage.

Recognition and Future Outlook

Steve Johansson, managing director of MedTech Breakthrough, highlights that the award showcases how the AdvanceAD-Tx test revolutionizes AD management by providing objective insights to enhance treatment selection. This accolade adds to Castle's growing list of awards recognizing its advancements in AI and oncology technologies, positioning the company at the forefront of the digital health innovation surge.

Commitment to Innovation

Castle Biosciences remains committed to developing innovative tests across various medical specialties, particularly in dermatologic and gastroenterological diseases. Their holistic approach to patient care aligns with the principles of personalized medicine, aiming to empower both patients and clinicians through science-backed solutions.

Through continued advancement and dedication to improving healthcare outcomes, Castle Biosciences is poised to further influence disease management in a rapidly evolving health landscape.